Targeting the NF-E2-related factor 2 pathway for overcoming leukemia.
AML
Blood cancer
Chemoresistance
Chemotherapy
Leukemia
NRF2
Oxidative stress
Pediatrics leukemia
ROS
Journal
International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578
Informations de publication
Date de publication:
31 Dec 2023
31 Dec 2023
Historique:
received:
25
03
2023
revised:
14
08
2023
accepted:
19
10
2023
medline:
24
11
2023
pubmed:
28
10
2023
entrez:
27
10
2023
Statut:
ppublish
Résumé
Leukemia is cancer of the body's blood-forming tissues, including the bone marrow and the lymphatic system. There are many types of leukemia that some of them occur in children and the others are more common in adults. Currently, there are many different chemotherapy agents for leukemia while chemoresistance increases the survival of the leukemic cells. One of the main reasons of chemoresistance, is a transcription factor called Nuclear factor erythroid 2-Related Factor 2 (NRF2). An increase in NRF2 expression in leukemic cells which are being treated with chemotherapy agents, can increase the survival of these cells in the presence of therapeutics. Accordingly, the inhibition of NRF2 by different methods as a cotreatment with classical chemotherapy agents, can be a promising procedure in leukemia treatment. In this study we focus on the association of NRF2 and leukemia and targeting it as a new therapeutic method in leukemia treatment.
Identifiants
pubmed: 37890739
pii: S0141-8130(23)04492-6
doi: 10.1016/j.ijbiomac.2023.127594
pii:
doi:
Substances chimiques
NF-E2-Related Factor 2
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
127594Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest There is no conflict of interest.